Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TUBB1 | Q9H4B7 | 16/20 | 0.76 |
| ▸ | TUBB4A | P04350 | 6/20 | 0.76 |
| ▸ | TUBB | P07437 | 6/20 | 0.76 |
| ▸ | TUBA3C | P0DPH7 | 6/20 | 0.76 |
| ▸ | TUBA1B | P68363 | 6/20 | 0.76 |
| ▸ | TUBA4A | P68366 | 6/20 | 0.76 |
| ▸ | TUBB4B | P68371 | 6/20 | 0.76 |
| ▸ | TUBB3 | Q13509 | 6/20 | 0.76 |
| ▸ | TUBB2A | Q13885 | 6/20 | 0.76 |
| ▸ | TUBB8 | Q3ZCM7 | 6/20 | 0.76 |
| ▸ | TUBA3E | Q6PEY2 | 6/20 | 0.76 |
| ▸ | TUBA1A | Q71U36 | 6/20 | 0.76 |
| ▸ | TUBA1C | Q9BQE3 | 6/20 | 0.76 |
| ▸ | TUBB6 | Q9BUF5 | 6/20 | 0.76 |
| ▸ | TUBB2B | Q9BVA1 | 6/20 | 0.76 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.76 |
| ▸ | SLCO2B1 | O94956 | 1/20 | 0.76 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.76 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.76 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.76 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13746940 | 0.92 | TUBB1 (0.62) | TUBB1TUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL14964022 | 0.90 | MMP2 (0.62) | TUBB1TUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL20105073 | 0.89 | TUBB1 (0.76) | TUBB1TUBB4ATUBBTUBA3CTUBA1B | |
| Combretastatin A4 SCHEMBL29355902 | 0.87 | TUBB1 (1.00) | TUBB1TUBB4ATUBBTUBA3CTUBA1B | |
| Combretastatin A4 SCHEMBL29501750 | 0.87 | TUBB1 (1.00) | TUBB1TUBB4ATUBBTUBA3CTUBA1B | |
| E-Combretastatin A-4 SCHEMBL9707931 | 0.87 | TUBB1 (1.00) | TUBB1TUBB4ATUBBTUBA3CTUBA1B | |
| Combretastatin A4 SCHEMBL18946 | 0.87 | TUBB1 (1.00) | TUBB1TUBB4ATUBBTUBA3CTUBA1B | |
| Combretastatin A4 SCHEMBL18945 | 0.87 | TUBB1 (1.00) | TUBB1TUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL10030788 | 0.86 | TUBB1 (0.64) | TUBB1TUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL10136222 | 0.86 | APP (0.65) | TUBB1TUBB4ATUBBTUBA3CTUBA1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120277251-A1 | ANALOGS OF DEHYDROPHENYLAHISTINS AND THEIR THERAPEUTIC USE | NEREUS PHARMACEUTICALS, INC. (US) | 2012-11-01 | — | — | US | disclosed |
| US-8247552-B2 | Analogs of dehydrophenylahistins and their therapeutic use | NEREUS PHARMACEUTICALS, INC. (US) | 2012-08-21 | — | — | US | disclosed |
| US-8129527-B2 | cancer and non-cancer diseases associated with vascular proliferation; mitoxantrone resistant, taxol resistant cancers | NEREUS PHARMACUTICALS, INC. (US) | 2012-03-06 | — | — | US | disclosed |
| US-20110245260-A1 | ANALOGS OF DEHYDROPHENYLAHISTINS AND THEIR THERAPEUTIC USE | NEREUS PHARMACEUTICALS, INC. (US) | 2011-10-06 | — | — | US | disclosed |
| US-7956058-B2 | Dehydrophenylahistins and analogs thereof and the synthesis of dehydrophenylahistins and analogs thereof | NEREUS PHARMACEUTICALS, INC. (US) | 2011-06-07 | — | — | US | disclosed |
| US-7935704-B2 | antiproliferative, antitumor agent; fungicide; inhibit eukaryotic cell cycle progression in M phase; rheumatoid arthritis, chronic articular rheumatism, psoriasis, diabetic retinopathy, neovascular glaucoma, retinopathy of prematurity, macular degeneration, corneal graft rejection, osteoporosis | NEREUS PHARMACEUTICALS, INC. (US) | 2011-05-03 | — | — | US | disclosed |
| US-7919497-B2 | Analogs of dehydrophenylahistins and their therapeutic use | NEREUS PHARMACEUTICALS, INC. (US) | 2011-04-05 | — | — | US | disclosed |
| US-7674903-B2 | Dehydrophenylahistins and analogs thereof and the synthesis of dehydrophenylahistins and analogs thereof | NEREUS PHARMACEUTICALS, INC. (US) | 2010-03-09 | — | — | US | disclosed |
| US-20080221122-A1 | ANALOGS OF DEHYDROPHENYLAHISTINS AND THEIR THEAPEUTIC USE | BEYONDSPRING PHARMACEUTICALS, INC. | 2008-09-11 | — | — | US | disclosed |
| WO-2007035841-A9 | ANALOGS OF DEHYDROPHENYLAHISTINS AND THEIR THERAPEUTIC USE | NEREUS PHARMACEUTICALS INC (US) | 2007-05-18 | — | — | WO | disclosed |
| US-20070078138-A1 | Analogs of dehydrophenylahistins and their therapeutic use | BEYONDSPRING PHARMACEUTICALS, INC. | 2007-04-05 | — | — | US | disclosed |
| WO-2007035841-A1 | ANALOGS OF DEHYDROPHENYLAHISTINS AND THEIR THERAPEUTIC USE | NEREUS PHARMACEUTICALS, INC. (US) | 2007-03-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110245260-A1 | ANALOGS OF DEHYDROPHENYLAHISTINS AND THEIR THERAPEUTIC USE | MKI67, HPGDS, HCCS | TUBB1 418/4885TUBB4A 258/4885TUBB 431/4885 |
| US-20070078138-A1 | Analogs of dehydrophenylahistins and their therapeutic use | MKI67, HPGDS, HCCS | TUBB1 418/4885TUBB4A 258/4885TUBB 431/4885 |
| US-20080221122-A1 | ANALOGS OF DEHYDROPHENYLAHISTINS AND THEIR THEAPEUTIC USE | HPGDS, DHPS, HCCS | TUBB1 747/4885TUBB4A 369/4885TUBB 803/4885 |
| US-20120277251-A1 | ANALOGS OF DEHYDROPHENYLAHISTINS AND THEIR THERAPEUTIC USE | MKI67, HPGDS, HCCS | TUBB1 418/4885TUBB4A 258/4885TUBB 431/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.